Improving Social Needs For Women With Gynecological Cancer Could Improve Outcomes and Lessen Healthcare Disparities

August 4, 2021 4:04 pm

By Ariana Pelosci

Women with gynecologic cancer who experience an improvement of social needs such as companionship and food insecurity could experience improved outcomes.

The identification of social needs and accompanying solutions could result in more actionable health care disparities … Read more

UT Southwestern finds crucial new molecular mechanisms and biomarkers in ovarian cancer

July 30, 2021 4:55 pm

DALLAS – July 30, 2021 – UT Southwestern faculty have discovered what appears to be an Achilles’ heel in ovarian cancers, as well as new biomarkers that could point to which patients are the best candidates for possible new treatments.… Read more

Can an Antibiotic Treat Cancers that Become Resistant to PARP Inhibitors?

July 27, 2021 12:44 pm

For a second time, researchers will test an antibiotic discovered in the 1950s as a potential treatment for cancer.

The first attempt to study the drug, novobiocin, in patients with cancer was a small clinical trial conducted 30 years ago. … Read more

Organ-on-a-Chip Finds Crucial Connection Between Blood and Ovarian Cancers

July 26, 2021 4:48 pm

Researchers at Texas A&M University are pushing organ-on-a-chip devices to new levels that could change the way clinicians approach cancer treatment, particularly ovarian cancer. A team has recently submitted a patent disclosure with the Texas A&M Engineering Experiment Station.… Read more

Study shows cancer misinformation common on social media sites

July 22, 2021 2:40 pm

A new study published online today in the Journal of the National Cancer Institute reports that one third of the most popular cancer treatment articles on social media contain misinformation. Further, the vast majority of that misinformation has the potential … Read more

Ceralasertib Olaparib Combo Elicits Promising Activity In Parp Resistant Ovarian Cancer

July 15, 2021 2:43 pm

The combination of ceralasertib and olaparib induced clinical activity and was well tolerated in patients with homologous recombination deficient, recurrent platinum-sensitive, PARP inhibitor–resistant ovarian cancer.

The combination of ceralasertib and olaparib (Lynparza) induced clinical activity and was well tolerated in … Read more

HIPEC/Carboplatin Does Not Show Significant Results in Ovarian Cancer

July 14, 2021 3:37 pm

By Ariana Pelosci

A new phase 2 study shows that patients who were treated with HIPEC and Carboplatin, did not have better progression-free or overall survival.

Although hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin appeared to be well tolerated in patients … Read more

Virtual biopsies may give more accurate results than traditional method thanks to revolutionary technique

July 11, 2021 3:17 pm

CAMBRIDGE, England — Virtual biopsies could replace invasive tissue procedures and give more accurate results thanks to a revolutionary new method developed using computer scans. The new advanced computing technique uses routine medical scans to enable doctors to take fewer, … Read more

Could a DNA Blood Test Spot a Range of Hidden Cancers?

June 25, 2021 9:14 am

By Alan Mozes

Could a new one-and-done blood test designed to detect as many as 50 different types of cancer become a diagnostic game changer?

Yes, say researchers, who report the method appears accurate and reliable at identifying and locating … Read more

Old Antibiotic Targets BRCA-Mutated, PARP Inhibitor-Resistant Tumors

June 18, 2021 12:21 pm

Studies in laboratory cell lines and in mouse tumor models show an antibiotic developed in the 1950s called novabiocin effectively targets and kills cancer cells with abnormal BRCA1 or BRCA2 genes, which normally help to repair damaged DNA.… Read more

Cancer Patients See High Seroconversion Rates After COVID Vax

June 11, 2021 9:21 am

By Mike Bassett

Dampened responses seen in those with hematological malignancies, however patients with cancer who were vaccinated against COVID-19 achieved high seroconversion rates, a single-center study found.

The rate of seroconversion was especially high among patients with solid tumors … Read more

Novel vaccine safe, effective in ovarian cancer subset

June 11, 2021 8:51 am

By Jennifer Southall

A novel vaccine appeared safe and demonstrated clinical benefit as front-line maintenance therapy for women with advanced-stage ovarian cancer, according to results of a phase 2b trial presented during the virtual ASCO Annual Meeting.… Read more

Universal Genetic Testing Is Far From a Reality in Patients With Ovarian Cancer

June 8, 2021 11:28 am

by Victoria Forster, PhD

Rates of genetic testing in ovarian cancer “remain well below the goal of universal testing,” according to authors of a systematic review and meta-analysis published in Gynecologic Oncology.1Read more

Pafolacianine Sodium, NIRF Imaging Adjunct May Yield Benefit in FR+ Ovarian Cancer

June 8, 2021 11:16 am

Experts reveal pafolacianine sodium may offer a novel real-time adjunct to current surgical imaging practice in ovarian cancer surgery, according to a phase 3 study being presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.… Read more

Mirvetuximab Soravtansine Plus Bevacizumab Looks Promising in Platinum-Agnostic Ovarian Cancer

June 7, 2021 11:22 am

The combination of mirvetuximab soravtansine and bevacizumab produces “impressive antitumor activity” in patients with recurrent ovarian cancer and high folate receptor alpha (FRα) expression, according to researchers.… Read more

No Difference in Survival Noted With Longer Duration of Bevacizumab for Ovarian Cancer

June 7, 2021 11:18 am

Doubling treatment duration of bevacizumab did not lead to better survival in patients with ovarian cancer who were treated on a phase 3 trial.

For patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer, prolonged treatment

Read more

Electronic Olfaction System Under Study as Screening Tool for Pancreatic and Ovarian Cancers

June 5, 2021 9:00 am

An odor-based test that detects vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95% accuracy, according to a new study presented by Johnson et al during the 2021 … Read more

Pertuzumab/Trastuzumab Demonstrates Activity in Tissue-Agnostic Trial for Patients With HER2-Positive Tumors

June 4, 2021 10:34 am

Results from the phase II MyPathway basket trial found that the HER2-targeted therapies pertuzumab and trastuzumab demonstrated durable activity in patients with a wide variety of tumors marked by HER2 amplification or overexpression, although responses were limited in those with … Read more

HIPEC With Carboplatin for Platinum-Sensitive Recurrent Ovarian Cancer: Safety and Outcomes

June 2, 2021 12:29 pm

In an MSK Team Ovary–led phase II trial reported in the Journal of Clinical Oncology, Zivanovic et al found that use of hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin during secondary cytoreduction followed by chemotherapy did not improve 24-month progression-free … Read more

Cancer Patients Develop ‘Adequate’ Immune Response to COVID Vax

May 28, 2021 11:09 am

In a prospective study in Israel, 90% of cancer patients were seropositive for antibodies

By Mike Bassett

The vast majority of patients undergoing active systemic therapy for cancer exhibited an adequate immune response to the Pfizer/BioNTech COVID-19 vaccine, according to … Read more